ROSEN, A LONGSTANDING LAW FIRM, Encourages MoonLake Immunotherapeutics Investors to Secure Counsel Before Important Deadline in Securities Class Action - MLTXNovember 24, 2025 4:55 PM EST | Source: The Rosen Law Firm PANew York, New York--(Newsfile Corp. - November 24, 2025) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of MoonLake Immunotherapeutics (NASDAQ: MLTX) between March 10, 2024 and September 29, 2025, both dates inclusive (the "Class Per ...

NEW YORK, Nov. 24, 2025 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of MoonLake Immunotherapeutics (NASDAQ: MLTX). Shareholders who purchased shares of MLTX during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. CONTACT US HERE: https://securitiesclasslaw.com/securities/moonlake-loss-submission-form/?id=178594&from=3 CLASS PERIOD: March 1 ...

PHILADELPHIA, Nov. 24, 2025 /PRNewswire/ -- National plaintiffs' law firm Berger Montague PC announces a class action lawsuit against MoonLake Immunotherapeutics (NASDAQ: MLTX) ("MoonLake" or the "Company") on behalf of investors who purchased MoonLake shares during the period of March 10, 2024 through September 29, 2025 (the "Class Period"). Accessibility StatementSkip Navigation Investor Deadline: Investors who purchased MoonLake securities during the Class Period may, no later than December 15, 2025, ...

MOONLAKE NOTICE: MoonLake Immunotherapeutics (MLTX) Faces Securities Fraud Allegations after Stock Drops 90%, Investors Urged to Contact BFA LawNovember 24, 2025 6:08 AM EST | Source: Bleichmar Fonti & AuldNew York, New York--(Newsfile Corp. - November 24, 2025) - Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against MoonLake Immunotherapeutics (NASDAQ: MLTX) and certain of the Company's senior executives for potential violations of the federal ...

ROSEN, A RANKED AND LEADING LAW FIRM, Encourages MoonLake Immunotherapeutics Investors to Secure Counsel Before Important Deadline in Securities Class Action - MLTXNovember 23, 2025 1:17 PM EST | Source: The Rosen Law Firm PANew York, New York--(Newsfile Corp. - November 23, 2025) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of MoonLake Immunotherapeutics (NASDAQ: MLTX) between March 10, 2024 and September 29, 2025, both dates inclusive (the "Cla ...

MLTX INVESTOR REMINDER: Faruqi & Faruqi, LLP Announces that MoonLake Investors Have Opportunity to Lead Class Action LawsuitNovember 23, 2025 8:02 AM EST | Source: Faruqi & Faruqi LLPFaruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses in MoonLake to Contact Him Directly to Discuss Their OptionsIf you purchased or acquired securities in MoonLake between March 10, 2024 and September 29, 2025 and would like to discuss your legal rights, ...

NEW YORK, Nov. 23, 2025 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against MoonLake Immunotherapeutics (NASDAQ: MLTX) and certain of the Company’s senior executives for potential violations of the federal securities laws. If you invested in MoonLake, you are encouraged to obtain additional information by visiting: https://www.bfalaw.com/cases/moonlake-immunotherapeutics-class-action-lawsuit. Investors have until December 15, 2025, to as ...

NEW YORK, Nov. 22, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of MoonLake Immunotherapeutics (NASDAQ: MLTX) between March 10, 2024 and September 29, 2025, both dates inclusive (the “Class Period”), of the important December 15, 2025 lead plaintiff deadline. SO WHAT: If you purchased MoonLake common stock during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency ...

MLTX SHAREHOLDER ALERT: Faruqi & Faruqi, LLP Announces that MoonLake Investors Have Opportunity to Lead Class Action LawsuitNovember 22, 2025 7:44 AM EST | Source: Faruqi & Faruqi LLPFaruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses in MoonLake to Contact Him Directly to Discuss Their OptionsIf you purchased or acquired securities in MoonLake between March 10, 2024 and September 29, 2025 and would like to discuss your legal rights, ...

诉讼背景 - 领先证券律师事务所Bleichmar Fonti & Auld LLP宣布，已对MoonLake Immunotherapeutics及其部分高级执行官提起集体诉讼，指控其可能违反联邦证券法 [2] - 诉讼代表MoonLake普通股投资者，依据1934年证券交易法第10(b)条和第20(a)条提出索赔，案件由美国纽约南区联邦地区法院审理，案件名称为Peters v MoonLake Immunotherapeutics, et al, No 1:25-cv-08612 [4] - 投资者需在2025年12月15日前向法院申请担任首席原告 [4] 指控核心 - 公司是一家临床阶段生物技术公司，专注于开发炎症性疾病疗法，在相关期间进行了备受期待的sonelokimab三期VELA试验，用于治疗中重度化脓性汗腺炎成人患者 [5] - 公司向投资者宣传其“强大的临床数据”及Nanobody结构优于竞争对手的传统单克隆抗体疗法，可转化为更高的临床应答率并提供差异化机会 [6] - 指控称，公司的临床数据和Nanobody结构实际上并未带来优于竞争对手的临床益处，这令药物获得监管批准和商业可行性的前景受到质疑 [7] 市场影响 - 2025年9月28日，公司公布VELA三期试验第16周结果，两项试验结果均令人失望，其中VELA-2试验未达到主要终点 [8] - 此消息导致公司股价从2025年9月26日的每股61.99美元暴跌至2025年9月29日的每股6.24美元，下跌55.75美元，跌幅近90% [8]